|
1
|
Liu W, Choueiri TK and Cho E: Statin use
and the risk of renal cell carcinoma in 2 prospective US cohorts.
Cancer. 118797–803. 2012.PubMed/NCBI
|
|
2
|
Heart Protection Study Collaborative
Group: MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised
placebo-controlled trial. Lancet. 360:7–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hebert PR, Gaziano JM, Chan KS and
Hennekens CH: Cholesterol lowering with statin drugs, risk of
stroke, and total mortality. An overview of randomized trials.
JAMA. 278:313–321. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forrester JS and Libby P: The inflammation
hypothesis and its potential relevance to statin therapy. Am J
Cardiol. 99:732–738. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Demierre MF, Higgins PD, Gruber SB, Hawk E
and Lippman SM: Statins and cancer prevention. Nat Rev Cancer.
5:930–942. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Woodard J, Sassano A, Hay N and Platanias
LC: Statin-dependent suppression of the Akt/mammalian target of
rapamycin signaling cascade and programmed cell death 4
up-regulation in renal cell carcinoma. Clin Cancer Res.
14:4640–4649. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khurana V, Caldito G and Ankem M: Statins
might reduce risk of renal cell carcinoma in humans: case-control
study of 500,000 veterans. Urology. 71:118–122. 2008. View Article : Google Scholar
|
|
9
|
Sivaprasad U, Abbas T and Dutta A:
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase
inhibitors on the cell cycle of prostate cancer cells. Mol Cancer
Ther. 5:2310–2316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shepherd J, Cobbe SM, Ford I, et al:
Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia. West of Scotland Coronary Prevention Study
Group. N Engl J Med. 333:1301–1307. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sacks FM, Pfeffer MA, Moye LA, et al: The
effect of pravastatin on coronary events after myocardial
infarction in patients with average cholesterol levels. Cholesterol
and Recurrent Events Trial investigators. N Engl J Med.
335:1001–1009. 1996. View Article : Google Scholar
|
|
12
|
Young-Xu Y, Jabbour S, Goldberg R, et al:
Usefulness of statin drugs in protecting against atrial
fibrillation in patients with coronary artery disease. Am J
Cardiol. 92:1379–1383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cipollone F, Fazia M, Iezzi A, et al:
Suppression of the functionally coupled
cyclooxygenase-2/prostaglandin E synthase as a basis of
simvastatin-dependent plaque stabilization in humans. Circulation.
107:1479–1485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krupski WC, Layug EL, Reilly LM, et al:
Comparison of cardiac morbidity between aortic and infrainguinal
operations. Study of Perioperative Ischemia (SPI) Research Group. J
Vasc Surg. 15:354–365. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bax L, Mali WP, Buskens E, et al: The
benefit of STent placement and blood pressure and lipid-lowering
for the prevention of progression of renal dysfunction caused by
Atherosclerotic ostial stenosis of the Renal artery. The
STAR-study: rationale and study design. J Nephrol. 16:807–812.
2003.
|
|
16
|
Farmer JA: Pleiotropic effects of statins.
Curr Atheroscler Rep. 2:208–217. 2000. View Article : Google Scholar
|
|
17
|
Rao S, Lowe M, Herliczek TW, et al:
Lovastatin mediated G1 arrest in normal and tumor breast cells is
through inhibition of CDK2 activity and redistribution of p21 and
p27, independent of p53. Oncogene. 17:2393–2402. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vincent L, Chen W, Hong L, et al:
Inhibition of endothelial cell migration by cerivastatin, an
HMG-CoA reductase inhibitor: contribution to its anti-angiogenic
effect. FEBS Lett. 495:159–166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cafforio P, Dammacco F, Gernone A, et al:
Statins activate the mitochondrial pathway of apoptosis in human
lymphoblasts and myeloma cells. Carcinogenesis. 26:883–891. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marcelli M, Cunningham GR, Haidacher SJ,
et al: Caspase-7 is activated during lovastatin-induced apoptosis
of the prostate cancer cell line LNCaP. Cancer Res. 58:76–83.
1998.PubMed/NCBI
|
|
21
|
Hindler K, Cleeland CS, Rivera E and
Collard CD: The role of statins in cancer therapy. Oncologist.
11:306–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coogan PF, Rosenberg L, Palmer JR, et al:
Statin use and the risk of breast and prostate cancer.
Epidemiology. 13:262–267. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Poynter JN, Gruber SB, Higgins PD, et al:
Statins and the risk of colorectal cancer. N Engl J Med.
352:2184–2192. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Strandberg TE, Pyorala K, Cook TJ, et al:
Mortality and incidence of cancer during 10-year follow-up of the
Scandinavian Simvastatin Survival Study (4S). Lancet. 364:771–777.
2004.PubMed/NCBI
|
|
25
|
ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group: Major outcomes in moderately
hypercholesterolemic, hypertensive patients randomized to
pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA.
288:2998–3007. 2002. View Article : Google Scholar
|
|
26
|
Simes RJ, Marschner IC, Hunt D, et al:
Relationship between lipid levels and clinical outcomes in the
Long-term Intervention with Pravastatin in Ischemic Disease (LIPID)
Trial: to what extent is the reduction in coronary events with
pravastatin explained by on-study lipid levels? Circulation.
105:1162–1169. 2002. View Article : Google Scholar
|
